FAP and neoplasm: Fibroblast activation protein (FAP) IL2 variant (FAP-IL2v, also referred to as simlukafusp alfa or RO6874281) is a novel, monomeric, immune-cytokine designed to overcome the limitations of wild-type IL2 by selectively promoting immune responses in the tumor microenvironment (4).